International Clinical Psychopharmacology最新文献_第5页

Understanding mood disorder treatments. 了解情绪障碍的治疗方法。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000573

Alessandro Serretti

引用次数: 0

Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial. 番红花辅助利培酮治疗精神分裂症阴性症状：一项随机、双盲、安慰剂对照试验

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-12-12 DOI: 10.1097/YIC.0000000000000575

Siamand Mazhar, Ahmad Shamabadi, Kimia Kazemzadeh, Mohammad Aidin Farahvash, Atiye Heidari Dalfard, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh

{"title":"Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial.","authors":"Siamand Mazhar, Ahmad Shamabadi, Kimia Kazemzadeh, Mohammad Aidin Farahvash, Atiye Heidari Dalfard, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh","doi":"10.1097/YIC.0000000000000575","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000575","url":null,"abstract":"Current treatments for schizophrenia encounter resistance, limited efficacy, and limiting complications, necessitating novel approaches. The effects of saffron on negative symptoms were investigated as it has shown neuroprotective and antipsychotic properties. Fifty-six clinically stable chronic schizophrenic outpatients were equally assigned to saffron 15 mg q12hr or placebo groups while continuing risperidone. The Positive and Negative Syndrome Scale (PANSS) was used to assess schizophrenia-related symptoms in weeks 4 and 8. Also, the patients were assessed for the Hamilton depression rating scale (HDRS) and adverse effects. The baseline characteristics of the groups were comparable (Ps > 0.05). There were significant time-treatment interaction effects on negative ( = 0.137), general psychopathology ( = 0.193), and total ( = 0.113) PANSS scores. Affirmatively, their reductions were significantly greater in the saffron group until weeks 4 (Cohen's ds = 0.922, 0.898, and 0.759, respectively) and 8 (Cohen's ds = 0.850, 1.047, and 0.705, respectively). Regarding the negative symptoms, a better 25% response rate was obtained in the saffron group until the endpoint (P = 0.003). The HDRS scores, extrapyramidal symptom rating scale scores, and side effect frequencies were comparable between the groups (Ps > 0.05). Saffron was beneficial for primary negative symptoms of chronic schizophrenia in a safe and tolerable manner. It also outperformed placebo in improving general psychopathology and total symptoms.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder. 非沉浸式与沉浸式虚拟现实之间的情感识别差异：精神分裂症和双相情感障碍的初步研究结果。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-12-06 DOI: 10.1097/YIC.0000000000000576

Mauro Scala, Daniel Sánchez-Reolid, Roberto Sánchez-Reolid, Patricia Fernández-Sotos, Verónica Romero-Ferreiro, Miguel Ángel Alvarez-Mon, Guillermo Lahera, Giuseppe Fanelli, Alessandro Serretti, Chiara Fabbri, Antonio Fernández-Caballero, Roberto Rodriguez-Jimenez

{"title":"Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder.","authors":"Mauro Scala, Daniel Sánchez-Reolid, Roberto Sánchez-Reolid, Patricia Fernández-Sotos, Verónica Romero-Ferreiro, Miguel Ángel Alvarez-Mon, Guillermo Lahera, Giuseppe Fanelli, Alessandro Serretti, Chiara Fabbri, Antonio Fernández-Caballero, Roberto Rodriguez-Jimenez","doi":"10.1097/YIC.0000000000000576","DOIUrl":"10.1097/YIC.0000000000000576","url":null,"abstract":"Deficits in social cognition may impair emotional processing and facial emotional recognition (FER) in patients with bipolar disorder (BD) and schizophrenia. FER is generally explored using photographs or images of static faces that do not fully capture the complexity of real-life facial stimuli. To overcome this limitation, we developed a set of dynamic virtual faces depicting six basic emotions (i.e. happiness, sadness, anger, fear, disgust, and surprise) and a neutral expression suitable for presentation in immersive and nonimmersive virtual realities. This study presents preliminary findings on the differences in FER accuracy from a frontal view between immersive and nonimmersive virtual realities among patients experiencing a relapse of schizophrenia ( n = 10), a manic phase of BD ( n = 10), and a group of healthy controls (HCs) ( n = 10). As a secondary objective, we compare the FER accuracy across these three groups. Patients with schizophrenia and BD showed similar accuracy in recognizing emotions in immersive and nonimmersive virtual reality settings. However, patients with schizophrenia exhibited lower FER accuracy than HCs in both settings. Individuals with BD showed intermediate accuracy between those with schizophrenia and HCs, although these differences were not statistically significant. Notably, recognition of negative emotions was significantly impaired in both groups of patients.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Catatonia as a debut of systemic lupus erythematosus: a case report on a diagnostic challenge. 作为系统性红斑狼疮首发症状的紧张症：诊断难题的病例报告。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-19 DOI: 10.1097/YIC.0000000000000572

Helena Andreu, Blanca Serra-Sarró, Laura Bueno, Òscar de Juan, Iñaki Ochandiano, Luis Olivier, Helena Álvarez, Ailin Herrero, Cecilia Mantellini, Miguel Vicente, Maria Sagué-Vilavella, Lidia Ilzarbe, Luis Pintor, Marina Garriga, Vicent Llorca-Bofí, Miquel Bioque

引用次数: 0

A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. 文拉法辛和纳曲酮预防曲马多所致阿片类药物使用障碍患者复发的疗效比较研究。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000487

Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly

{"title":"A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol.","authors":"Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly","doi":"10.1097/YIC.0000000000000487","DOIUrl":"10.1097/YIC.0000000000000487","url":null,"abstract":"Tramadol and venlafaxine share similar pharmacological characteristics that may allow for overlapping therapeutic indications for them. The objective of this study was to compare the efficacy of venlafaxine and naltrexone in the treatment of tramadol abuse. This comparative trial included 95 patients with tramadol abuse who were detoxified for 2 weeks. Twenty-eight participants underwent the maintenance phase, while the remaining participants (n = 67) dropped out. The patients were randomized to use 50 mg/day of naltrexone or 225 mg/day of venlafaxine for 8 weeks. All participants were interviewed using SCID-I (DSM-IV-TR) criteria for diagnosing substance use and other psychiatric disorders. The proportion of relapsed patients was comparable between the naltrexone and venlafaxine groups (29.4% vs. 30.4%, P = 0.9). However, participants in the venlafaxine group stayed in treatment longer than participants in the naltrexone group, and the difference was significant (22.9 ± 7.89 days vs. 16.9 ± 3.4 days, P = 0.01). Only psychiatric comorbidity was found to be significantly associated with retention in treatment (80% vs. 22%, P = 0.005). Venlafaxine is as effective as naltrexone in preventing relapse in patients with tramadol abuse. Venlafaxine was more effective than naltrexone in treatment retention.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"341-349"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients. 英国医用大麻登记处：分析医用大麻治疗广泛性焦虑症患者临床疗效的病例系列。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-02-02 DOI: 10.1097/YIC.0000000000000536

Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren

{"title":"UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients.","authors":"Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren","doi":"10.1097/YIC.0000000000000536","DOIUrl":"10.1097/YIC.0000000000000536","url":null,"abstract":"This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome measures (PROMs) from baseline up to 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L. Adverse events were recorded using CTCAE version 4.0. A total of 120 patients were identified for inclusion, of which 38 (31.67%), 52 (43.33%), and 30 (25.00%) were prescribed oils, dried flower, and both formulations of CBMP. Associated improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, 6, and 12 months were observed compared to baseline ( P < 0.010). There were 24 (20.00%) patients who reported 442 (368.33%) adverse events, most of which were mild (n = 184, 41.63%) and moderate (n = 197, 44.57%). This study reports an association between initiation of a homogeneous CBMP therapy and improvements in anxiety severity and HRQoL in individuals with GAD. Moreover, therapy was well-tolerated at 12 months follow-up. Further investigation through randomized controlled trials will ultimately be required to determine causation.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"350-360"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venlafaxine for tramadol dependence and medical cannabis therapy for generalized anxiety disorder. 文拉法辛治疗曲马多依赖症和医用大麻治疗广泛性焦虑症。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-09-25 DOI: 10.1097/YIC.0000000000000567

Alessandro Serretti

引用次数: 0

Suicide in prison in the North of Italy (1993-2022): a case-control study examining differences between suicides inside and outside prison. 意大利北部监狱中的自杀事件（1993-2022 年）：一项病例对照研究，探讨监狱内外自杀事件的差异。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-10-09 DOI: 10.1097/YIC.0000000000000569

Raffaella Calati, Stefano Tambuzzi, Rosa Gravagnuolo, Livio Muscatiello, Maria Elena Magrin, Franca Crippa, Fabio Madeddu, Riccardo Zoja, Guendalina Gentile

{"title":"Suicide in prison in the North of Italy (1993-2022): a case-control study examining differences between suicides inside and outside prison.","authors":"Raffaella Calati, Stefano Tambuzzi, Rosa Gravagnuolo, Livio Muscatiello, Maria Elena Magrin, Franca Crippa, Fabio Madeddu, Riccardo Zoja, Guendalina Gentile","doi":"10.1097/YIC.0000000000000569","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000569","url":null,"abstract":"Prisoners constitute a group at suicide risk, showing higher relative rates of suicides than the general population. However, there is limited knowledge about the characteristics of those who die by suicide in Italian prisons. Based on the total sample of suicides of the Institute of Forensic Medicine of Milan (1993-2022), suicides in prison (N = 120) were matched by age and gender with cases that occurred outside prison (N = 300) and compared with them. The considered variables were sociodemographic, clinical, and suicide-related. Univariate analyses and logistic regression model were performed. In univariate analyses, suicides in prison showed higher rates of ethnicity different from white Caucasian, lower rates of depression, higher rates of alcoholism, addiction, respiratory system diseases, hepatitis, and amyotrophic lateral sclerosis, lower use of any medication, and in particular psychotropic medications, and a higher percentage of violent suicide method versus nonviolent compared to suicides outside prison. In the logistic regression model, ethnicity, depression, and addiction were the only features differentiating suicides in prison from ones outside prison. Particular attention should be paid to inmates with non-white ethnicity and those with addiction. Ensuring adequate access to psychiatric care and implementing comprehensive suicide prevention strategies within Italian prisons is crucial.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of efficacy of long-acting injectable antipsychotics on caregivers' burden of patients with schizophrenia. 长效注射抗精神病药物的疗效对精神分裂症患者护理负担的影响。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-02-22 DOI: 10.1097/YIC.0000000000000539

Enrico Capuzzi, Cecilia Quitadamo, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli

引用次数: 0

The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia. 早或晚服用长效抗精神病药物对精神分裂症患者照顾者负担的影响。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-11-23 DOI: 10.1097/YIC.0000000000000524

Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü

{"title":"The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia.","authors":"Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü","doi":"10.1097/YIC.0000000000000524","DOIUrl":"10.1097/YIC.0000000000000524","url":null,"abstract":"The effective treatment in the early stages of schizophrenia is of critical importance to improve the prognosis. Schizophrenia affects patients' relatives too. The effects of early or late initiation of long-acting injectable antipsychotics (LAI-APs) on the patient have been shown, yet their effects on the caregiver are still unknown. We aimed to determine how the time of initiation of LAI-APs affects the caregiver burden by comparing the patients who were started on LAI-APs in the first 5 years of diagnosis and those who were started at a later period. Patients were classified as 'early-LAI' and 'late-LAI' according to the time of initiation of a LAI-AP. Their caregivers were also classified as the same way, as 'caregiver-early' and 'caregiver-late' and were compared in terms of caregiver burden. The quality of life, depression, anxiety, and caregiver burden scores of the caregiver-late group were significantly worse. The time of initiation of LAI-APs and the functioning levels of the patients were found to be determinant factors for the caregiver burden. This is the first study to investigate the effects of LAI-AP's initiation time on the caregivers to our knowledge. The use of LAI-APs in the early stages is associated with better outcomes for the caregiver.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"313-322"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0